<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277600</url>
  </required_header>
  <id_info>
    <org_study_id>206285</org_study_id>
    <secondary_id>AI438-044</secondary_id>
    <nct_id>NCT02277600</nct_id>
  </id_info>
  <brief_title>A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)</brief_title>
  <official_title>Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male
      and female subjects. There is no formal hypothesis, however, it is expected that the
      coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase
      the systemic exposure of BMS-626529.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2014</start_date>
  <completion_date type="Actual">January 12, 2015</completion_date>
  <primary_completion_date type="Actual">January 12, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (maximum observed plasma concentration and area under the concentration-time curve in 1 dosing interval) for BMS-626529</measure>
    <time_frame>predose and up to 12 hours post dose on Days 4 and 14</time_frame>
    <description>In the presence or absence of multiple doses of DRV/COBI or COBI</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety as assessed by adverse events and other physical parameters</measure>
    <time_frame>From dosing (Day 1) to Day 14</time_frame>
    <description>Collection of adverse events and other physical parameters to assess safety and tolerability</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Treatment A, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A:
BMS-663068 orally twice daily (BID) on Days 1 through 4
Treatment B:
BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Treatment C, D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment C:
BMS-663068 orally BID on Days 1 through 4
Treatment D:
BMS-663068 orally BID plus COBI QD on Days 5 through 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Cohort 2, Treatment C, D</arm_group_label>
    <arm_group_label>Cohort 1, Treatment A, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir</description>
    <arm_group_label>Cohort 1, Treatment A, B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobicistat</intervention_name>
    <description>Cobicistat</description>
    <arm_group_label>Cohort 2, Treatment C, D</arm_group_label>
    <arm_group_label>Cohort 1, Treatment A, B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female

          -  Nonsmoking subjects

          -  Ages 18 to 50 years

          -  Inclusive with a body mass index of 18.0 to 32.0 kg/m2, inclusive

          -  Women of childbearing potential

          -  Must agree to follow instructions for methods of contraception for the duration of the
             study plus 34 days post-treatment completion

        Exclusion Criteria:

          -  Any history of acute or chronic medical and surgical illness.

          -  Personal of family history of hemophilia A or B

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

